A higher incidence of smooth endoplasmic reticulum clusters with aromatase inhibitors.
aromatase inhibitor
clomiphene citrate
estradiol
progesterone
smooth endoplasmic reticulum
Journal
Reproductive medicine and biology
ISSN: 1445-5781
Titre abrégé: Reprod Med Biol
Pays: Japan
ID NLM: 101213278
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
18
06
2019
revised:
27
07
2019
accepted:
08
08
2019
entrez:
15
10
2019
pubmed:
15
10
2019
medline:
15
10
2019
Statut:
epublish
Résumé
This study aimed to analyze whether a regimen of aromatase inhibitor (AI) could reduce the occurrence of smooth endoplasmic reticulum clusters (sERCs) in oocytes. The AI and the clomiphene citrate (CC) regimens were compared, regarding the sERC (+) rates and the serum estradiol and progesterone levels on the date of hCG administration, and the duration of AI, CC, and hMG administration. The occurrence of sERCs in oocytes from patients treated with AI was significantly higher than that in oocytes from those treated with CC. Both the serum estradiol and progesterone levels were found to be significantly higher in sERC (+) than in sERC (-) cycles. With regard to the CC cycles, no significant differences were detected. The duration of AI and hMG administration was longer for sERC (+) than for sERC (-) cycles. As AI did not reduce the occurrence of sERCs, the elevation of estradiol may not be the cause of sERC occurrence but a consequence. Considering the higher levels of progesterone and longer duration of hMG in sERC (+) cycles, the negative effects of premature luteinization, which frequently occur with the AI protocol, should be investigated further.
Identifiants
pubmed: 31607799
doi: 10.1002/rmb2.12296
pii: RMB212296
pmc: PMC6780026
doi:
Types de publication
Journal Article
Langues
eng
Pagination
384-389Informations de copyright
© 2019 The Authors. Reproductive Medicine and Biology published by John Wiley & Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.
Déclaration de conflit d'intérêts
Hiroe Saito, Junko Otsuki, Hiromi Takahashi, Rei Hirata, Toshihiro Habara and Nobuyoshi Hayashi declare that they have no conflicts of interest.
Références
Reprod Med Biol. 2019 Sep 11;18(4):384-389
pubmed: 31607799
Mol Hum Reprod. 2018 Jun 1;24(6):310-317
pubmed: 29635518
J Assist Reprod Genet. 2018 May;35(5):899-905
pubmed: 29357025
N Engl J Med. 2003 Jun 12;348(24):2431-42
pubmed: 12802030
Fertil Steril. 2016 Dec;106(7):1718-1724
pubmed: 27743693
J Assist Reprod Genet. 2014 Nov;31(11):1461-7
pubmed: 25205205
J Clin Oncol. 2005 Jul 1;23(19):4347-53
pubmed: 15824416
Hum Reprod. 2017 Apr 1;32(4):750-757
pubmed: 28333241
Fertil Steril. 2011 Jul;96(1):143-149.e7
pubmed: 21621206
Biopharm Drug Dispos. 2001 Jul;22(5):191-7
pubmed: 11745921
Hum Reprod. 2004 Jul;19(7):1591-7
pubmed: 15180981
Hum Reprod. 2013 Aug;28(8):2111-7
pubmed: 23696540
Fertil Steril. 2009 Oct;92(4):1496.e1-1496.e3
pubmed: 19646689
Reprod Biomed Online. 2008 Jan;16(1):113-8
pubmed: 18252056
Reprod Biomed Online. 2017 Apr;34(4):337-344
pubmed: 28169188